Although RSV is a frequent cause of acute respiratory infections (ARIs), an estimation of its incidence has proven challenging due to a lack of routine testing, overlapping clinical presentations with ...

Credit: Getty Images. RSV primarily affects children and older adults, and can lead to severe illness or death. Respiratory syncytial virus (RSV) affects infants, young children, and older adults, ...

Respiratory syncytial virus (RSV) is a common respiratory virus which usually causes mild, cold-like symptoms during the respiratory virus season. However, especially among young infants under six ...

Respiratory syncytial virus (RSV) is a common virus that affects the throat, nose, and lungs. Symptoms include a runny nose, congestion, sneezing, wheezing, cough, and fever, and these are often mild ...

As several European countries are currently detecting respiratory syncytial virus (RSV) infections, ECDC issues rapid scientific advice for policymakers and public health authorities on ways to ...

Oct. 3, 2024 -- Respiratory Syncytial Virus (RSV) is often thought of as a childhood illness, but it poses a significant threat to older adults as well. According to the CDC, RSV infected ...

ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection through 5 months, a typical RSV season, with the same dose regardless of ...

European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season ENFLONSIA ...

The respiratory syncytial virus prefusion F protein (RSVpreF) vaccine was highly effective against RSV-related acute respiratory illness (ARI) requiring emergency care or hospitalization, including in ...

Breakthrough mRNA technologies, strong U.S. leadership, and rising awareness of RSV risks fuel unprecedented market expansion.Austin, United States, April 27, 2026 (GLOBE NEWSWIRE) -- According to SNS ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIA™ (clesrovimab) for the ...

ENFLONSIA is a preventive monoclonal antibody designed to protect infants against a spectrum of RSV disease severity, including worsening disease requiring hospitalization ENFLONSIA is the first and ...